# A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease

> **NCT04609397** · PHASE2 · TERMINATED · sponsor: **Tianjin Hemay Pharmaceutical Co., Ltd** · enrollment: 89 (actual)

## Conditions studied

- Behçet Disease

## Interventions

- **DRUG:** Hemay005
- **DRUG:** Hemay005
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04609397
- **Lead sponsor:** Tianjin Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-30
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-04-30
- **Target enrollment:** 89 (ACTUAL)
- **Why stopped:** The study purpose has been achieved
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609397, "A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04609397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*